Targeting cancer stem cells with phytochemicals

Molecular Interventions

Volumn 8, Issue 4, 2008, Pages 174-184

  Kawasaki, Brian T ^a   Hurt, Elaine M ^a   Mistree, Tashan ^a   Farrar, William L ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 PHENYLENE BIS(METHYLENE)SELENOCYANATE; ALPHA TOCOPHEROL; BETA CATENIN; BREAST CANCER RESISTANCE PROTEIN; CELECOXIB; CURCUMIN; CYCLOPAMINE; DOCOSAHEXAENOIC ACID; EPIGALLOCATECHIN GALLATE; GEMCITABINE; GENISTEIN; GLYCOPROTEIN P; GOSSYPOL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 4; MULTIDRUG RESISTANCE PROTEIN 5; NOTCH RECEPTOR; PARTHENOLIDE; PLANT MEDICINAL PRODUCT; RECOMBINANT INTERLEUKIN 2; RESVERATROL; RETINOIC ACID RECEPTOR; SELENIUM; SELENIUM DERIVATIVE; SILYMARIN; SONIC HEDGEHOG PROTEIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VITAMIN D; WNT PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BLADDER CANCER; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER STEM CELL; CELL DIFFERENTIATION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; COLON CANCER; DRUG MECHANISM; ENDOMETRIUM CANCER; ESOPHAGUS CANCER; FEVER; HEADACHE; HUMAN; LEUKEMIA; LUNG CANCER; MELANOMA; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; NONHUMAN; OSTEOSARCOMA; PANCREAS TUMOR; PROSTATE CANCER; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; SKIN CARCINOMA; SQUAMOUS CELL CARCINOMA; THYROID CANCER; UTERINE CERVIX CANCER;

ANIMALS; APOPTOSIS; DRUG RESISTANCE, NEOPLASM; HUMANS; MODELS, BIOLOGICAL; NEOPLASTIC STEM CELLS; PHYTOTHERAPY; PLANT PREPARATIONS; SIGNAL TRANSDUCTION;

EID: 53549083542     PISSN: 15340384     EISSN: 15432548     Source Type: Journal    
DOI: 10.1124/mi.8.4.9     Document Type: Review

References (106)

1. Ichim, C.V. and Wells, R.A. First among equals: The cancer cell hierarchy. Leuk. Lymphoma 47, 2017-2027 (2006).
2. Clarke, M.F. and Fuller, M. Stem cells and cancer: Two faces of eve. Cell 124, 1111-1115 (2006).
3. Dean, M., Fojo, T., and Bates, S. Tumour stem cells and drug resistance. Nat. Rev. Cancer 5, 275-284 (2005).
4. Huntly, B.J. and Gilliland, D.G. Leukaemia stem cells and the evolution of cancer-stem-cell research. Nat. Rev. Cancer 5, 311-321 (2005).
5. Pardal, R., Clarke, M.F., and Morrison, S.J. Applying the principles of stem-cell biology to cancer. Nat. Rev. Cancer 3, 895-902 (2003).
6. Bjerkvig, R., Tysnes, B.B., Aboody, K.S., Najbauer, J., and Terzis, A.J. The origin of the cancer stem cell: Current controversies and new insights. Nat. Rev. Cancer 5, 899-904 (2005).
7. Hurt, E.M. and Farrar, W.L. Cancer stem cells: The seeds of metastasis? Mol. Interv. 8, 140-142 (2008).
8. Kasper, S. Exploring the origins of the normal prostate and prostate cancer stem cell. Stem Cell Rev. doi 10.1007/s12015-008-9033-1 (2008).
9. Wu, X.Z. Origin of cancer stem cells: The role of self-renewal and differentiation. Ann. Surg. Oncol. 15, 407-414 (2008)
10. Lapidot, T., Sirard, C., Vormoor, J. et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 367, 645-648 (1994).
11. Bonnet, D. and Dick, J.E. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat. Med. 3, 730-737 (1997).
12. Al-Hajj, M., Wicha, M.S., Benito-Hernandez, A., Morrison, S.J., and Clarke, M.F. Prospective identification of tumorigenic breast cancer cells. Proc. Natl. Acad. Sci. U. S. A 100, 3983-3988 (2003).
13. Fang, D., Nguyen, T.K., Leishear, K. et al. A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Res. 65, 9328-9337 (2005).
14. Singh, S.K., Clarke, I.D., Terasaki, M., Bonn, V.E., Hawkins, C., Squire, J., and Dirks, P.B. Identification of a cancer stem cell in human brain tumors. Cancer Res. 63, 5821-5828 (2003).
15. Kim, C.F., Jackson, E.L., Woolfenden, A.E., Lawrence, S., Babar, I., Vogel, S., Crowley, D., Bronson, R.T., and Jacks, T. Identification of bronchioalveolar stem cells in normal lung and lung cancer. Cell 121, 823-835 (2005).
16. O'Brien, C.A., Pollett, A., Gallinger, S., and Dick, J.E. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 445, 106-110 (2007).
17. Li, C., Heidt, D.G., Dalerba, P., Burant, C.F., Zhang, L., Adsay, V., Wicha, M., Clarke, M.F., and Simeone, D.M. Identification of pancreatic cancer stem cells. Cancer Res. 67, 1030-1037 (2007).
18. Monzani, E., Facchetti, F., Galmozzi, E. et al. Melanoma contains CD133 and ABCG2 positive cells with enhanced tumourigenic potential. Eur. J. Cancer 43, 935-946 (2007).
19. Polyak, K. and Hahn, W.C. Roots and stems: Stem cells in cancer. Nat. Med. 12, 296-300 (2006).
20. Patrawala, L., Calhoun, T., Schneider-Broussard, R. et al. Highly purified CD44+ prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells. Oncogene 25, 1696-1708 (2006).
21. Liu, S., Dontu, G., and Wicha, M.S. Mammary stem cells, self-renewal pathways, and carcinogenesis. Breast Cancer Res. 7, 86-95 (2005).
22. Clement, V., Sanchez, P., de, Tribolet N., Radovanovic, I., and Altaba, A. HEDGEHOG-GLI1 signaling regulates human glioma growth, cancer stem cell self-renewal, and tumorigenicity. Curr. Biol. 17, 165-172 (2007).
23. Liu, S., Dontu, G., Mantle, I.D., Patel, S., Ahn, N.S., Jackson, K.W., Suri, P., and Wicha, M.S. Hedgehog signaling and Bmi-1 regulate self-renewal of normal and malignant human mammary stem cells. Cancer Res. 66, 6063-6071 (2006).
24. Dontu, G., Abdallah, W.M., Foley, J.M., Jackson, K.W., Clarke, M.F., Kawamura, M.J., and Wicha, M.S. In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev. 17, 1253-1270 (2003).
25. Hurt, E. M., Kawasaki, B.T., Klarmann, G.J., Thomas, S.B., and Farrar, W.L. CD44+ CD24- prostate cells are early cancer progenitor/stem cells that provide a model for patients with poor prognosis. Br. J. Cancer 98, 756-765 (2008).
26. Clarke, M.F. A self-renewal assay for cancer stem cells. Cancer Chemother. Pharmacol. 56 Suppl 1, 64-68 (2005).
27. Ichikawa, H., Nakamura, Y., Kashiwada, Y., and Aggarwal, B.B. Anticancer drugs designed by mother nature: Ancient drugs but modern targets. Curr. Pharm. Des 13, 3400-3416 (2007).
28. Lev-Ari, S., Vexler, A., Starr, A., shkenazy-Voghera, M., Greif, J., Aderka, D., and Ben-Yosef, R. Curcumin augments gemcitabine cytotoxic effect on pancreatic adenocarcinoma cell lines. Cancer Invest 25, 411-418 (2007).
29. Christensen, J.G. and LeBlanc, G.A. Reversal of multidrug resistance in vivo by dietary administration of the phytochemical indole-3-carbinol. Cancer Res. 56, 574-581 (1996).
30. Karmakar, S., Banik, N.L., and Ray, S.K. Molecular mechanism of inositol hexaphosphate-mediated apoptosis in human malignant glioblastoma T98G cells. Neurochem. Res. 32, 2094-2102 (2007).
31. Singh, S.K., Hawkins, C., Clarke, I.D., Squire, J.A., Bayani, J., Hide, T., Henkelman, R. M., Cusimano, M.D., and Dirks, P.B. Identification of human brain tumour initiating cells. Nature 432, 396-401 (2004).
32. Hermann, P.C., Huber, S.L., Herrler, T., Aicher, A., Ellwart, J.W., Guba, M., Bruns, C.J., and Heeschen, C. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 1, 313-323 (2007).
33. Aggarwal, B.B., Sethi, G., Baladandayuthapani, V., Krishnan, S., and Shishodia, S. Targeting cell signaling pathways for drug discovery: An old lock needs a new key. J. Cell Biochem. 102, 580-592 (2007).
34. Bettuzzi, S., Brausi, M., Rizzi, F., Castagnetti, G., Peracchia, G., and Corti, A. Chemoprevention of human prostate cancer by oral administration of green tea catechins in volunteers with high-grade prostate intraepithelial neoplasia: A preliminary report from a one-year proof-of-principle study. Cancer Res. 66, 1234-1240 (2006).
35. Shankar, S., Ganapathy, S., and Srivastava, R.K. Green tea polyphenols: Biology and therapeutic implications in cancer. Front Biosci. 12, 4881-4899 (2007).
36. Deeb, K.K., Trump, D.L., and Johnson, C.S. Vitamin D signalling pathways in cancer: Potential for anticancer therapeutics. Nat. Rev. Cancer 7, 684-700 (2007).
37. Beer, T.M., Ryan, C.W., Venner, P.M. et al.Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: A report from the ASCENT Investigators. J. Clin. Oncol. 25, 669-674 (2007).
38. Gottesman, M.M. Mechanisms of cancer drug resistance. Annu. Rev. Med. 53, 615-627 (2002).
39. + cancer stem cells in glioblastoma. Mol. Cancer 5, 67 (2006).
40. Shervington, A. and Lu, C. Expression of multidrug resistance genes in normal and cancer stem cells. Cancer Invest 26, 535-542 (2008).
41. Keshet, G. I., Goldstein, I., Itzhaki, O. et al. MDR1 expression identifies human melanoma stem cells. Biochem. Biophys. Res. Commun. 368, 930-936 (2008).
42. Zhou, J., Wang, C. Y., Liu, T. et al.Persistence of side population cells with high drug efflux capacity in pancreatic cancer. World J. Gastroenterol. 14, 925-930 (2008).
43. Zhou, J., Zhang, H., Gu, P., Bai, J., Margolick, J.B., and Zhang, Y. NF-kappaB pathway inhibitors preferentially inhibit breast cancer stemlike cells. Breast Cancer Res. Treat. doi 10.1007/s10549-007-9798-y (2007).
44. Jodoin, J., Demeule, M., and Beliveau, R. Inhibition of the multidrug resistance P-glycoprotein activity by green tea polyphenols. Biochim. Biophys. Acta 1542, 149-159 (2002).
45. Mei, Y., Wei, D., and Liu, J. Reversal of cancer multidrug resistance by tea polyphenol in KB cells. J. Chemother. 15, 260-265 (2003).
46. Sadzuka, Y., Sugiyama, T., and Sonobe, T. Efficacies of tea components on doxorubicin induced antitumor activity and reversal of multidrug resistance. Toxicol. Lett. 114, 155-162 (2000).
47. Zhu, A., Wang, X., and Guo, Z. Study of tea polyphenol as a reversal agent for carcinoma cell lines' multidrug resistance (study of TP as a MDR reversal agent). Nucl. Med. Biol. 28, 735-740 (2001).
48. Wu, C.P., Calcagno, A.M., Hladky, S.B., Ambudkar, S.V., and Barrand, M.A. Modulatory effects of plant phenols on human multidrug-resistance proteins 1, 4 and 5 (ABCC1, 4 and 5). FEBS J. 272, 4725-4740 (2005).
49. Harbottle, A., Daly, A.K., Atherton, K., and Campbell, F.C. Role of glutathione S-transferase P1, P-glycoprotein and multidrug resistanceassociated protein 1 in acquired doxorubicin resistance. Int. J. Cancer 92, 777-783 (2001).
50. Verma, S.P., Goldin, B.R., and Lin, P.S. The inhibition of the estrogenic effects of pesticides and environmental chemicals by curcumin and isoflavonoids. Environ. Health Perspect. 106, 807-812 (1998).
51. Choi, B.H., Kim, C.G., Lim, Y., Shin, S.Y., and Lee, Y.H. Curcumin downregulates the multidrug-resistance mdr1b gene by inhibiting the PI3K/Akt/NFkappaB pathway. Cancer Lett. 259, 111-118 (2007).
52. Chearwae, W., Shukla, S., Limtrakul, P., and Ambudkar, S.V. Modulation of the function of the multidrug resistance-linked ATP-binding cassette transporter ABCG2 by the cancer chemopreventive agent curcumin. Mol. Cancer Ther. 5, 1995-2006 (2006).
53. Tang, D.G., Patrawala, L., Calhoun, T., Bhatia, B., Choy, G., Schneider-Broussard, R., and Jeter, C. Prostate cancer stem/progenitor cells: Identification, characterization, and implications. Mol. Carcinog. 46, 1-14 (2007).
54. Postovit, L.M., Costa, F.F., Bischof, J.M., Seftor, E.A., Wen, B., Seftor, R.E., Feinberg, A.P., Soares, M.B., and Hendrix, M.J. The commonality of plasticity underlying multipotent tumor cells and embryonic stem cells. J. Cell Biochem. 101, 908-917 (2007).
55. Hammerschmidt, M., Brook, A., and McMahon, A.P. The world according to hedgehog. Trends Genet. 13, 14-21 (1997).
56. Ingham, P.W. Transducing Hedgehog: The story so far. EMBO J. 17, 3505-3511 (1998).
57. Ehtesham, M., Sarangi, A., Valadez, J.G., Chanthaphaychith, S., Becher, M.W., Abel, T.W., Thompson, R.C., and Cooper, M.K. Ligand-dependent activation of the hedgehog pathway in glioma progenitor cells. Oncogene 26, 5752-5761 (2007).
58. Peacock, C.D., Wang, Q., Gesell, G.S. et al. Hedgehog signaling maintains a tumor stem cell compartment in multiple myeloma. Proc. Natl. Acad. Sci. U. S. A. 104, 4048-4053 (2007).
59. Feldmann, G., Dhara, S., Fendrich, V. et al. Blockade of hedgehog signaling inhibits pancreatic cancer invasion and metastases: A new paradigm for combination therapy in solid cancers. Cancer Res. 67, 2187-2196 (2007).
60. Cooper, M.K., Porter, J.A., Young, K.E., and Beachy, P.A. Teratogenmediated inhibition of target tissue response to Shh signaling. Science 280, 1603-1607 (1998).
61. Chen, J.K., Taipale, J., Cooper, M.K., and Beachy, P.A. Inhibition of Hedgehog signaling by direct binding of cyclopamine to Smoothened. Genes Dev. 16, 2743-2748 (2002).
62. Berman, D.M., Karhadkar, S.S., Hallahan, A.R. et al. Medulloblastoma growth inhibition by hedgehog pathway blockade. Science 297, 1559-1561 (2002).
63. Blank, U., Karlsson, G., and Karlsson, S. Signaling pathways governing stem-cell fate. Blood 111, 492-503 (2008).
64. Fodde, R. and Brabletz, T. Wnt/beta-catenin signaling in cancer stemness and malignant behavior. Curr. Opin. Cell Biol. 19, 150-158 (2007).
65. Reguart, N., He, B., Taron, M., You, L., Jablons, D.M., and Rosell, R. The role of Wnt signaling in cancer and stem cells. Future. Oncol. 1, 787-797 (2005).
66. Taipale, J. and Beachy, P.A. The Hedgehog and Wnt signalling pathways in cancer. Nature 411, 349-354 (2001).
67. Rao, C.V., Cooma, I., Rodriguez, J.G., Simi, B., El-Bayoumy, K., and Reddy, B.S. Chemoprevention of familial adenomatous polyposis development in the APC(min) mouse model by 1,4-phenylene bis(methylene) selenocyanate. Carcinogenesis 21, 617-621 (2000).
68. Kim, J., Zhang, X., Rieger-Christ, K.M., Summerhayes, I.C., Wazer, D.E., Paulson, K.E., and Yee, A.S. Suppression of Wnt signaling by the green tea compound (-)-epigallocatechin 3-gallate (EGCG) in invasive breast cancer cells. Requirement of the transcriptional repressor HBP1. J. Biol. Chem. 281, 10865-10875 (2006).
69. Byers, S. and Shah, S. Vitamin D and the regulation of Wnt/beta-catenin signaling and innate immunity in colorectal cancer. Nutr. Rev. 65, S118-S120 (2007).
70. Zeng, H. and Combs, G.F., Jr. Selenium as an anticancer nutrient: Roles in cell proliferation and tumor cell invasion. J. Nutr. Biochem. 19, 1-7 (2007).
71. Narayanan, B.A., Narayanan, N.K., Desai, D., Pittman, B., and Reddy, B.S. Effects of a combination of docosahexaenoic acid and 1,4-phenylene bis(methylene) selenocyanate on cyclooxygenase 2, inducible nitric oxide synthase and beta-catenin pathways in colon cancer cells. Carcinogenesis 25, 2443-2449 (2004).
72. Su, L.K., Kinzler, K.W., Vogelstein, B., Preisinger, A.C., Moser, A.R., Luongo, C., Gould, K.A., and Dove, W.F. Multiple intestinal neoplasia caused by a mutation in the murine homolog of the APC gene. Science 256, 668-670 (1992).
73. Bose, M., Hao, X., Ju, J., Husain, A., Park, S., Lambert, J. D., and Yang, C. S. Inhibition of tumorigenesis in ApcMin/+ mice by a combination of (-)-epigallocatechin-3-gallate and fish oil. J. Agric. Food Chem. 55, 7695-7700 (2007).
74. 3 promotes the differentiation of colon carcinoma cells by the induction of E-cadherin and the inhibition of beta-catenin signaling. J. Cell Biol. 154, 369-387 (2001).
75. Larriba, M.J., Valle, N., Palmer, H.G. et al. The inhibition of Wnt/betacatenin signalling by 1alpha,25-dihydroxyvitamin D3 is abrogated by Snail1 in human colon cancer cells. Endocr. Relat. Cancer 14, 141-151 (2007).
76. Chiba, S. Notch signaling in stem cell systems. Stem Cells 24, 2437-2447 (2006).
77. Androutsellis-Theotokis, A., Leker, R.R., Soldner, F. et al. Notch signalling regulates stem cell numbers in vitro and in vivo. Nature 442, 823-826 (2006).
78. Dontu, G., Jackson, K.W., McNicholas, E., Kawamura, M.J., Abdallah, W.M., and Wicha, M.S. Role of Notch signaling in cell-fate determination of human mammary stem/progenitor cells. Breast Cancer Res. 6, R605-R615 (2004).
79. Fan, X., Matsui, W., Khaki, L., Stearns, D., Chun, J., Li, Y.M., and Eberhart, C.G. Notch pathway inhibition depletes stem-like cells and blocks engraftment in embryonal brain tumors. Cancer Res. 66, 7445-7452 (2006).
80. Aggarwal, B.B., Bhardwaj, A., Aggarwal, R.S., Seeram, N.P., Shishodia, S., and Takada, Y. Role of resveratrol in prevention and therapy of cancer: Preclinical and clinical studies. Anticancer Res. 24, 2783-2840 (2004).
81. Das, D.K. and Maulik, N. Resveratrol in cardioprotection: A therapeutic promise of alternative medicine. Molecular Interventions 6, 36-47 (2006).
82. Cecchinato, V., Chiaramonte, R., Nizzardo, M., Cristofaro, B., Basile, A., Sherbet, G.V., and Comi, P. Resveratrol-induced apoptosis in human T-cell acute lymphoblastic leukaemia MOLT-4 cells. Biochem. Pharmacol. 74, 1568-1574 (2007).
83. Sethi, G., Sung, B., and Aggarwal, B.B. Nuclear factor-kappaB activation: From bench to bedside. Exp. Biol. Med. (Maywood.) 233, 21-31 (2008).
84. Orlowski, R.Z. and Baldwin, A.S., Jr. NF-kappaB as a therapeutic target in cancer. Trends Mol. Med. 8, 385-389 (2002).
85. Guzman, M.L., Neering, S.J., Upchurch, D., Grimes, B., Howard, D.S., Rizzieri, D.A., Luger, S.M., and Jordan, C.T. Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells. Blood 98, 2301-2307 (2001).
86. Guzman, M.L., Rossi, R.M., Karnischky, L., Li, X., Peterson, D.R., Howard, D.S., and Jordan, C.T. The sesquiterpene lactone parthenolide induces apoptosis of human acute myelogenous leukemia stem and progenitor cells. Blood 105, 4163-4169 (2005).
87. Sell, S. Potential gene therapy strategies for cancer stem cells. Curr. Gene Ther. 6, 579-591 (2006).
88. Sell, S. Cancer and stem cell signaling: A guide to preventive and therapeutic strategies for cancer stem cells. Stem Cell Rev. 3, 1-6 (2007).
89. Kristal, A.R. Vitamin A, retinoids and carotenoids as chemopreventive agents for prostate cancer. J. Urol. 171, S54-S58 (2004).
90. Marklund, M., Sjodal, M., Beehler, B.C., Jessell, T.M., Edlund, T., and Gunhaga, L. Retinoic acid signalling specifies intermediate character in the developing telencephalon. Development 131, 4323-4332 (2004).
91. Oren, T., Sher, J.A., and Evans, T. Hematopoiesis and retinoids: Development and disease. Leuk. Lymphoma 44, 1881-1891 (2003).
92. Clarke, N., Germain, P., Altucci, L., and Gronemeyer, H. Retinoids: Potential in cancer prevention and therapy. Expert. Rev. Mol. Med. 6, 1-23 (2004).
93. Drumea, K., Yang, Z.F., and Rosmarin, A. Retinoic acid signaling in myelopoiesis. Curr. Opin. Hematol. 15, 37-41 (2008).
94. Okuno, M., Kojima, S., Matsushima-Nishiwaki, R., Tsurumi, H., Muto, Y., Friedman, S. L., and Moriwaki, H. Retinoids in cancer chemoprevention. Curr. Cancer Drug Targets. 4, 285-298 (2004).
95. Sparreboom, A., Cox, M.C., Acharya, M.R., and Figg, W.D. Herbal remedies in the United States: Potential adverse interactions with anticancer agents. J. Clin. Oncol. 22, 2489-2503 (2004).
96. Jatoi, A., Ellison, N., Burch, P.A. et al. A phase II trial of green tea in the treatment of patients with androgen independent metastatic prostate carcinoma. Cancer 97, 1442-1446 (2003).
97. Choan, E., Segal, R., Jonker, D., Malone, S., Reaume, N., Eapen, L., and Gallant, V. A prospective clinical trial of green tea for hormone refractory prostate cancer: An evaluation of the complementary/alternative therapy approach. Urol. Oncol. 23, 108-113 (2005).
98. Dalais, F.S., Meliala, A., Wattanapenpaiboon, N., Frydenberg, M., Suter, D.A., Thomson, W.K., and Wahlqvist, M.L. Effects of a diet rich in phytoestrogens on prostate-specific antigen and sex hormones in men diagnosed with prostate cancer. Urology 64, 510-515 (2004).
99. Pendleton, J.M., Tan, W.W., Anai, S., Chang, M., Hou, W., Shiverick, K.T., and Rosser, C.J. Phase II trial of isoflavone in prostate-specific antigen recurrent prostate cancer after previous local therapy. BMC. Cancer 8, 132 (2008).
100. Van, Poznak C., Seidman, A.D., Reidenberg, M.M. et al. Oral gossypol in the treatment of patients with refractory metastatic breast cancer: A phase I/II clinical trial. Breast Cancer Res. Treat. 66, 239-248 (2001).
101. Zhang, Y., Jia, S., Liu, Y., Li, B., Wang, Z., Lu, H., and Zhu, C. A clinical study of all-trans-retinoid-induced differentiation therapy of advanced thyroid cancer. Nucl. Med. Commun. 28, 251-255 (2007).
102. Chiesa, M.D., Passalacqua, R., Michiara, M. et al. Tamoxifen vs Tamoxifen plus 13-cis-retinoic acid vs Tamoxifen plus Interferon alpha-2a as first-line endocrine treatments in advanced breast cancer: Updated results of a phase II, prospective, randomised multicentre trial. Acta Biomed. 78, 204-209 (2007).
103. Boorjian, S.A., Milowsky, M.I., Kaplan, J. et al. Phase 1/2 clinical trial of interferon alpha2b and weekly liposome-encapsulated all-trans retinoic acid in patients with advanced renal cell carcinoma. J. Immunother. 30, 655-662 (2007).
104. Soriano, A. O., Yang, H., Faderl, S. et al. Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome. Blood 110, 2302-2308 (2007).
105. Brewster, A.M., Lee, J.J., Clayman, G.L. et al. Randomized trial of adjuvant 13-cis-retinoic acid and interferon alfa for patients with aggressive skin squamous cell carcinoma. J. Clin. Oncol. 25, 1974-1978 (2007).
106. Michael, A., Hill, M., Maraveyas, A., Dalgleish, A., and Lofts, F. 13-cis-Retinoic acid in combination with gemcitabine in the treatment of locally advanced and metastatic pancreatic cancer - report of a pilot phase II study. Clin. Oncol. (R. Coll. Radiol. ) 19, 150-153 (2007).